First Generation Telmods
Summary
Class of drugs including:- Gerontib (Geron Biotech)
- Teromerin/Telomerin (Astellas Pharma Inc.)
- Vitahib (Sanofi)
Safety Profile
This class of drugs did not initially receive ethical, or reliable, safety data from trials. However as the drugs were rapidly taken up by billions globally, stage 4 safety reporting identified several side effects including:- Anaphylaxis;
- Increased risk of cancers of endodermal origin;
- Large and small bowel villous atrophy resulting in decreased enteral nutrient uptake
- Lipoatrophy of the head and internal redistribution;
- Increased risk of NAFLD;
- Nausea and vomiting;
- Diarrhoea and associated AKI
Administration
The preferred route of administration for First Generation Telmods is transdermally. Oral preparations are available but greatly increase risk of cancer in cells of endodermal origin, and hence are not licensed by the FDA, EMEA, and other medicines agencies globally (several countries have bowed before public pressure and licensed oral preparations despite the risks). Oral preparations are available in most countries but illegally under the control of criminal organisations.- Basic science - Stephanie R. Bailey, Robert L. Dilley, Catherine Weis, Nam Woo Cho, Johann Anderson, Roger A. Greenberg.
- Gerontib - Brandon Riggs (PI)
- Teromerin - Shunsuke Kagawa (PI)
- Vitahib - Marie LaRousse (PI)
Discovery
2024-2032
Remove these ads. Join the Worldbuilders Guild